Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adiposity in Assessing Muscle Health in Men Treated with ADT

Publish date:: May 24, 2019

Key clinical point: Androgen deprivation therapy (ADT) for prostate cancer (PCa) may decrease absolute lean mass (LM) and increase absolute fat mass (FM).

Major finding: Muscle mass, size, and strength are compromised in men treated with ADT after accounting for their increased adiposity or body size.

Study details: This cross-sectional study examined the influence of adiposity on total and appendicular LM, muscle cross-sectional, and muscle strength in 70 men treated with ADT for PCa compared with age-matched PCa and healthy controls.

Citation:

Owen PJ, et al. J Cachexia Sarcopenia Muscle. 2019 May 8. doi: 10.1002/jcsm.12446.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Prostate Cancer

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,